ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2603

What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?

Regan Arendse1, Boulos Haraoui2, Denis Choquette3, John Kelsall4, Philip Baer5, Dalton Sholter6, William G. Bensen7, Mary J. Bell8, Michelle Teo9, Emmanouil Rampakakis10, Eliofotisti Psaradellis11, Brendan Osborne12, Cathy Tkaczyk12, Karina Maslova13, Francois Nantel14 and Allen J Lehman13, 1University of Saskatchewan, Saskatoon, SK, Canada, 2Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 3Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, 6Rheumatology Associates, Edmonton, AB, Canada, 7St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 8Rheum Div, Sunnybrook Health Sciences Centre/University of Toronto, Toronto, ON, Canada, 9Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, 10JSS Medical Research, St-Laurent, QC, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada, 13Janssen Inc., Toronto, ON, Canada, 1419 Green belt Dr, Janssen Inc., Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: anti-TNF therapy, Health Assessment Questionnaire, outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose :

The
Health Assessment Questionnaire (HAQ) remains the gold standard for measuring patient-reported
functional status in rheumatoid arthritis (RA) and is included among the
measures suggested by the American College of Rheumatology for making treatment
decisions in routine care. We have previously shown that significant
variability exists in the correlation of individual HAQ questions with
patient-reported and clinical outcomes. The aim of this analysis was to assess,
in routine care, the timelines of HAQ improvement as compared to clinical
improvement and to examine possible differences in the improvement of
individual questions.

Methods :

BioTRAC
is an ongoing, prospective registry of patients initiating treatment for RA,
ankylosing spondylitis, or psoriatic arthritis with infliximab (IFX) or golimumab
(GLM). Eligible people for this analysis included RA patients treated with IFX
who were enrolled since 2002 or with GLM enrolled since 2010. Time to achieving
minimal important difference (MID; Δ≥0.22) in HAQ, HAQ≤1,
minimal disease (MD) in individual HAQ questions (no or some difficulty), CDAI
low disease activity (LDA), or CDAI remission was assessed with the
Kaplan-Maier estimator of the survival function and cox regression.

Results:

A
total of 1205 patients (75.3% female) were included with mean (SD) age of 56.0
(13.6) years and disease duration of 8.4 (8.9) years at baseline. Mean (SD) HAQ
and CDAI were 1.55 (0.72) and 33.8 (17.4), respectively.

Statistically
significant and clinically meaningful improvements in both HAQ and CDAI were
observed over time. The cumulative probability of achieving HAQ MID,
HAQ≤1, CDAI LDA, and CDAI remission by 12 months was 69.5%, 54.5%, 54.1%,
and 18.1%, respectively. Time to achieving HAQ MID [Hazard Ratio (95% CI): 3.6
(3.2-4.2)], HAQ≤1 [2.9 (2.6-3.4)], and CDAI LDA [3.1 (2.7-3.6)] was
significantly lower as compared to CDAI remission.

With
respect to individual HAQ questions, at baseline, the most predominant usual
activities that patients were unable to do were taking a tub bath (27.9% of
patients), reaching and getting down a 5-pound object from the head (21.8%),
and doing chores such as vacuuming or yard work (23.2%). In accordance, time to
having no or some difficulty in these activities was significantly higher
compared to the remaining HAQ items (Figure 1).     

Conclusion:

The
results of this analysis show that the timelines for achieving HAQ targets in
routine care is comparable to that of achieving CDAI LDA. Significant
differences were observed in terms of improvement in individual HAQ items with
the inability to take a tub bath, getting heavy overhead objects down, and
doing chores being the most persistent.

Figure
1. Time to Having No Difficulty or Some Difficulty in Individual HAQ Questions

 

 

 

 


Disclosure: R. Arendse, Janssen Inc., 5; B. Haraoui, Janssen Inc.,, 5; D. Choquette, Janssen Inc., 5,AbbVie, 5,Amgen, 5,Celgene, 5,BMS, 5,Pfizer Inc, 5; J. Kelsall, Janssen Inc., 5; P. Baer, Janssen Inc., 5,AbbVie, 5,Amgen, 5,BMS, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5; D. Sholter, Janssen Inc., 5; W. G. Bensen, Janssen Inc., 5; M. J. Bell, Janssen Inc., 5; M. Teo, Janssen Inc., 5; E. Rampakakis, JSS Medical Research, a Contract Research Organization, 3; E. Psaradellis, JSS Medical Research, 3; B. Osborne, Janssen Inc., 3; C. Tkaczyk, Janssen Inc., 3; K. Maslova, Janssen Inc., 3; F. Nantel, Janssen Inc., 3; A. J. Lehman, Janssen Inc., 3.

To cite this abstract in AMA style:

Arendse R, Haraoui B, Choquette D, Kelsall J, Baer P, Sholter D, Bensen WG, Bell MJ, Teo M, Rampakakis E, Psaradellis E, Osborne B, Tkaczyk C, Maslova K, Nantel F, Lehman AJ. What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/what-is-the-variability-of-haq-over-time-in-patients-with-rheumatoid-arthritis-treated-with-anti-tnf/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-variability-of-haq-over-time-in-patients-with-rheumatoid-arthritis-treated-with-anti-tnf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology